

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)*, of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Energy and Commerce

Subcommittee: Oversight and Investigations

Hearing Date: April 10, 2019

Hearing Title :

Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin

Witness Name: Michael B. Mason

Position/Title: Senior Vice President, Connected Care and Insulins

Witness Type: ☐ Governmental ☒ Non-governmental

Are you representing yourself or an organization? ☐ Self ☒ Organization

If you are representing an organization, please list what entity or entities you are representing:

Eli Lilly and Company

If you are a non-governmental witness, please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current calendar year and previous two calendar years. Include the source and amount of each grant or contract. *If necessary, attach additional sheet(s) to provide more information.*

Please see attached.

Because these are indefinite-quantity/indefinite supply contracts, there is no fixed contract amount.

If you are a non-governmental witness, please list any contracts or payments originating with a foreign government and related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current year and previous two calendar years. Include the amount and country of origin of each contract or payment. *If necessary, attach additional sheet(s) to provide more information.*

While Eli Lilly's foreign operations may have sales of insulins to foreign governments, Eli Lilly's U.S. insulin business has not received any contracts or payments originating with a foreign government related to the hearing's subject matter from 2017-2019.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.

Witness signature

Date

4/8/19

If you are a non-governmental witness, please ensure that you attach the following documents to this disclosure. Check both boxes to acknowledge that you have done so.

- ☒ Written statement of proposed testimony
- ☒ Curriculum vitae or biography

*Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a nongovernmental capacity, a written statement of proposed testimony shall include a curriculum vitae and a disclosure of any Federal grants or contracts, or contracts or payments originating with a foreign government, received during the current calendar year or either of the two previous calendar years by the witness or by an entity represented by the witness and related to the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B) shall include—

- (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and
- (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form not later than one day after the witness appears.

- (i) National Drug Rebate Agreement between the Secretary of Health and Human Services and Eli Lilly and Company, update effective as of September 13, 2018 for Labeler Code 00002
- (ii) National Drug Rebate Agreement between the Secretary of Health and Human Services and Eli Lilly and Company, update effective as of September 13, 2018 for Labeler Code 00777
- (iii) National Drug Rebate Agreement between the Secretary of Health and Human Services and Eli Lilly and Company, update effective as of September 13, 2018 for Labeler Code 66733
- (iv) Addendum to Pharmaceutical Pricing Agreement between the Secretary of Health and Human Services and Eli Lilly and Company, effective June 24, 2018 for Labeler Codes 00002 and 00777
- (v) Addendum to Pharmaceutical Pricing Agreement between the Secretary of Health and Human Services and Eli Lilly and Company, effective August 22, 2018 for Labeler Code 66733
- (vi) Federal Supply Schedule (FSS) Contract 36F79718D05031, effective August 1, 2018 through July 31, 2023 for all items awarded under Schedule 65 I B - *Drugs, Pharmaceuticals, and Hematology Products under Federal Supply Schedule Solicitation M5-Q50A-03-R7*
- (vii) Mass Modification to Federal Supply Schedule (FSS) Contract 36F79718D05031, effective July 15, 2018
- (viii) Mass Modification to Federal Supply Schedule (FSS) Contract 36F79718D05031, effective October 9, 2018